Poolbeg Pharma (POLB) is set to present new data on its lead asset POLB 001 at the European Hematology Association Congress in Stockholm next month, adding further visibility to its cancer immunotherapy programme.
The clinical-stage biopharmaceutical company said the poster presentation will highlight additional evidence supporting POLB 001 as a potential preventative treatment for cytokine release syndrome (CRS), a serious side effect associated with certain cancer immunotherapies.
The data will include in vivo models showing POLB 001’s ability to reduce multiple CRS-related cytokines, including tumour necrosis factor, interferon gamma, and interleukin-6. In vitro findings indicate the oral p38 mitogen-activated protein kinase (MAPK) inhibitor can suppress cytokine production without compromising bispecific antibody-driven tumour cell killing.
The presentation will take place during Poster Session 2 on 13 June at the Stockholmsmässan exhibition centre in Stockholm. EHA is regarded as one of the leading international scientific meetings in haematology, providing a major platform for emerging therapeutic data.
Poolbeg Pharma’s Principal Scientist Liam Tremble said: “We look forward to sharing this important data at the European Hematology Association Congress, one of the world's leading forums for advancing haematology research. The findings highlight the potential of POLB 001 to reduce key drivers of CRS while preserving anti-tumour activity. We believe POLB 001 could transform the cancer immunotherapy field through the prevention of CRS, improving patient quality of life and expanding the number of patients that can receive these life-saving cancer immunotherapies.”
View from Vox
For Poolbeg, continued evidence that POLB 001 can reduce CRS without weakening anti-cancer efficacy supports the broader investment case around a differentiated supportive cancer therapy.